<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079282</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4685-03</org_study_id>
    <nct_id>NCT05079282</nct_id>
  </id_info>
  <brief_title>Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma</brief_title>
  <official_title>An Open-label, Multi-center, Non-randomized Phase I Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, pharmacokinetics, and preliminary&#xD;
      efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs).</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Adverse events with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 used as a guide for the grading of severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate of Maximum Tolerate Dose (MTD)</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>MTD will be estimated based on Dose limiting toxicity (DLT) observed during the first 3 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of ONO-4685</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Plasma concentration will be assessed to evaluate Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Anti-Drug Antibody (ADA)</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>ADA to ONO-4685 will be assessed to evaluate potential immunogenicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of ONO-4685</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Antitumor Activity of ONO-4685 will be assessed according to the response criteria for Lymphoma.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Relapsed or Refractory T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>ONO-4685 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4685</intervention_name>
    <description>ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed</description>
    <arm_group_label>ONO-4685 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients aged â‰¥ 18 years at time of screening&#xD;
&#xD;
          2. Written informed consent by the patient or the patients' legally authorized&#xD;
             representative prior to screening&#xD;
&#xD;
          3. Patients with histologically or cytologically confirmed diagnosis of one of the&#xD;
             following subtypes of T-cell lymphoma:&#xD;
&#xD;
               1. Peripheral T-cell lymphoma (PTCL): Angioimmunoblastic T-cell lymphoma (AITL),&#xD;
                  PTCL, not otherwise specified (PTCL-NOS), nodal PTCL with T-follicular helper&#xD;
                  (TFH) and follicular T-cell lymphoma (FTCL)&#xD;
&#xD;
               2. Cutaneous T-cell lymphoma (CTCL) (stages II-B, III, and IV): Mycosis fungoides&#xD;
                  (MF) and Sezary syndrome (SS)&#xD;
&#xD;
          4. Patients must have received at least 2 prior systemic therapies.&#xD;
&#xD;
          5. Patients with PTCL must have at least 1 measurable lesion&#xD;
&#xD;
          6. Patients with CTCL must have assessable disease by response criteria for CTCL (Olsen&#xD;
             EA, 2011)&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 0-2&#xD;
&#xD;
          8. Life expectancy of at least 3 months&#xD;
&#xD;
          9. Adequate bone marrow, renal and hepatic functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with central nervous system (CNS) involvement&#xD;
&#xD;
          2. Patients with Adult T-cell leukemia/lymphoma (ATLL)&#xD;
&#xD;
          3. Prior allogeneic stem cell transplant&#xD;
&#xD;
          4. Prior treatment with ONO-4685, anti-PD-1, anti-PD-L1, anticytotoxic T lymphocyte&#xD;
             associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically&#xD;
             targeting T-cell co-stimulation or checkpoint pathways&#xD;
&#xD;
          5. Patients with malignancies (other than T-cell lymphoma) except for completely resected&#xD;
             basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, or any other&#xD;
             malignancies that has not relapsed for at least 2 years&#xD;
&#xD;
          6. History of severe allergy or hypersensitivity to any monoclonal antibodies, other&#xD;
             therapeutic proteins or corticosteroid (e.g., dexamethasone)&#xD;
&#xD;
          7. History of infection with Mycobacterium tuberculosis within 2 years prior to the first&#xD;
             dose of study treatment&#xD;
&#xD;
          8. Patients with systemic and active infection including human immunodeficiency virus&#xD;
             (HIV), hepatitis B or C virus infection&#xD;
&#xD;
          9. Patients not recovered to Grade 1 or stabilized from the adverse effects (excluding&#xD;
             alopecia) of any prior therapy for their malignancies&#xD;
&#xD;
         10. Women who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryota Shiibashi</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharma USA Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ono Pharmaceutical Co. Ltd Medical Information Center</last_name>
    <email>clinical_trial@ono.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ONO-4685</keyword>
  <keyword>PD-1</keyword>
  <keyword>CD3</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>PTCL</keyword>
  <keyword>AITL</keyword>
  <keyword>PTCL-NOS</keyword>
  <keyword>nodal PTCL with TFH</keyword>
  <keyword>FTCL</keyword>
  <keyword>CTCL</keyword>
  <keyword>MF</keyword>
  <keyword>SS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_url>https://www.ono.co.jp/eng/rd/policy.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

